The Melanoma Nursing Initiative – Home › Forums › Immunotherapy › Expectations for therapy › Adjuvant Immunotherapy in stage IIIA patients › Reply To: Adjuvant Immunotherapy in stage IIIA patients
March 5, 2018 at 3:13 pm #4730
Expert NurseSuzanne McGettigan
Such an interesting discussion.
Another factor that is influencing this group of patients is the results from the MSLT-II trial which demonstrated no increased benefit on overall survival for patients with microscopic disease undergoing completion lymph node dissection. From a practical standpoint, this potentially means that more patients will be classified as Stage IIIa now than previously. Therefore, it will continue to be a detailed conversation with patients about the role of adjuvant therapy in that setting.